DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates
Recent clinical isolates of key Gram-negative and Gram-positive bacteria were collected in 2012 from hospitalised patients in medical centres in four European countries (France, Germany, Italy and Spain) and were tested using standard broth microdilution methodology to assess the impact of 4 mg/L avibactam on the in vitro activities of ceftazidime, ceftaroline and aztreonam. Against Enterobacteriaceae, addition of avibactam significantly enhanced the level of activity of these antimicrobials. MIC90 values (minimum inhibitory concentration that inhibits 90% of the isolates) of ceftazidime, ceftaroline and aztreonam for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Morganella morganii were reduced up to 128-fold or greater when combined with avibactam. A two-fold reduction in the MIC90 of ceftazidime to 8 mg/L was noted in Pseudomonas aeruginosa isolates when combined with avibactam, whereas little effect of avibactam was noted on the MIC values of the test compounds when tested against Acinetobacter baumannii isolates. Avibactam had little effect on the excellent activity of ceftazidime, ceftaroline and aztreonam against Haemophilus influenzae. It had no impact on the in vitro activity of ceftazidime and ceftaroline against staphylococci and streptococci. This study demonstrates that addition of avibactam enhances the activities of ceftazidime, ceftaroline and aztreonam against Enterobacteriaceae and P. aeruginosa but not against A. baumannii., This study was funded by a grant from AstraZeneca and Actavis (formerly Forest Laboratories). The research of GMR is funded by the European Commission [grant EvoTar-FP7-HEALTH-F3-2011-2011-282004]. The research of HS at the Institute for Microbiology, Immunology and Hygiene (University Hospital of Cologne, Cologne, Germany) is supported by the German Center for Infection Research (DZIF) and the European Union, Directorate General for Research and Innovation through the Seventh Framework Program for Office of Research and Development [MagicBullet, grant agreement 278232]. The research of RC at the Microbiology Department of Ramón y Cajal University Hospital (Madrid, Spain) is funded by the European Commission [grants R-GNOSIS-FP7-HEALTH-F3-2011-282512, MON4STRAT-FP7-HEALTH-2013-INNOVATION-1-602906-2] and the Instituto de Salud Carlos III of Spain [FIS PI12/00734] and co-financed by the European Development Regional Fund [A Way to Achieve Europe program; Spanish Network for Research in Infectious Diseases grant REIPI RD12/0015].
Project:
EC / FP7 282004
,
EC / FP7 278232
,
EC / FP7 282512
,
EC / FP7 602906
View at: http://hdl.handle.net/10261/199634